Ginsenoside F2 treatment attenuates TPA-induced ear skin inflammation.
Ginsenoside F2 treatment decreases migration of IL-17A producing cells.
Dermal γδ T cells are the major producer of IL-17A in skin inflammation.
Ginsenoside F2 treatment decreases migration and ROS generation of neutrophils.